Prodrug Systems (I): Lipid-Based Doxorubicin Prodrugs and Their Nanodelivery Systems

doi:10.21127/yaoyimr20200013

Abstract

Abstract: Using natural lipids to covalently connect with antitumor agents to construct lipid-based molecular prodrugs and their nanosystems is a promising research frontier for sustainable medicinal chemistry, nanobiotechnology and tumor chemotherapy. This paper reviewed recent progress of lipid-based doxorubicin (molecular) prodrugs and their nanodelivery systems, including lipid-doxorubicin prodrugs, stimuli-responsive lipid-doxorubicin prodrugs, and lipid-doxorubicin prodrug-based drug co-delivery nanosystems. Additionally, possible future research outlooks in this field were also discussed.

Key words: lipid, doxorubicin, prodrugs, stimuli-responsive, drug co-delivery, nanosystems

Filipe Olim, Ana Rute Neves, Zhao Wang, Jingjing Sun, Helena Tomás, and Ruilong Sheng. Prodrug Systems (I): Lipid-Based Doxorubicin Prodrugs and Their Nanodelivery Systems[J]. Medicine Research, 2020, 4(1-2): 200013-200013.

References

[1] Baillet, J.; Desvergnes, V.; Hamoud, A.; Latxague, L.; Barthélémy, P. Lipid and nucleic acid chemistries: combining the best of both worlds to construct advanced biomaterials. Adv. Mater. 2018, 30, 1705078.
[2] (a) Grimaldi, N.; Andrade, F.; Segovia, N.; Ferrer-Tasies, L.; Sala, S.; Veciana, J.; Ventosa, N. Lipid-based nanovesicles for nanomedicine. Chem. Soc. Rev. 2016, 45, 6520–6545; (b) Karthivashan, G.; Ganesan, P.; Park, S. Y.; Lee, H. W.; Choi, D. K. Lipid-based nanodelivery approaches for dopamine-replacement therapies in Parkinson's disease: From preclinical to translational studies. Biomaterials 2020, 232, 119704.
[3] (a) Zaro, J. L. Lipid-Based drug carriers for prodrugs to enhance drug delivery. AAPS J. 2015, 17, 83–92; (b) Markovic, M.; Ben-Shabat, S.; Keinan, S.; Aponick, A.; Zimmermann, E. M.; Dahan, A. Lipidic prodrug approach for improved oral drug delivery and therapy. Med. Res. Rev. 2019, 39, 579–607.
[4] (a) Cao, Z. T.; Chen, Z. Y.; Sun, C. Y.; Li, H. J.; Wang, H. X.; Cheng, Q. Q.; Zuo, Z. Q.; Wang, J. L.; Liu, Y. Z.; Wang, Y.-C.; Wang, J. Overcoming tumor resistance to cisplatin by cationic lipid-assisted prodrug nanoparticles. Biomaterials 2016, 94, 9–19; (b) Cheetham, A. G.; Chakroun, R. W.; Ma, W.; Cui, H. Self-assembling prodrugs. Chem. Soc. Rev. 2017, 46, 6638–6663; (c) Nicolas, J. Drug-Initiated synthesis of polymer prodrugs: combining simplicity and efficacy in drug delivery. Chem. Mat. 2016, 28, 1591–1606; (d) Su, H.; Zhang, W.; Wang, H.; Wang, F.; Cui, H., Paclitaxel- promoted supramolecular polymerization of peptide conjugates. J. Am. Chem. Soc. 2019, 141, 11997–12004; (e) Cao, D.; He, J.; Xu, J.; Zhang, M.; Zhao, L.; Duan, G.; Cao, Y.; Zhou, R.; Ni, P. Polymeric prodrugs conjugated with reduction-sensitive dextran– camptothecin and pH-responsive dextran–doxorubicin: an effective combinatorial drug delivery platform for cancer therapy. Polym. Chem. 2016, 7, 4198–4212.
[5] (a) Sreekanth, V.; Bajaj, A., Recent advances in engineering of lipid drug conjugates for cancer therapy. ACS Biomater. Sci. Eng. 2019, 5, 4148–4166; (b) Schiapparelli, P.; Zhang, P.; Lara-Velazquez, M.; Guerrero-Cazares, H.; Lin, R.; Su, H.; Chakroun, R. W.; Tusa, M.; Quiñones-Hinojosa, A.; Cui, H. Self-assembling and self-formul- ating prodrug hydrogelator extends survival in a glioblastoma resection and recurrence model. J. Control. Release 2020, 319, 311–321.
[6] (a) Maksimenko, A.; Dosio, F.; Mougin, J.; Ferrero, A.; Wack, S.; Reddy, L. H.; Weyn, A. A.; Lepeltier, E.; Bourgaux, C.; Stella, B.; Cattel, L.; Couvreur, P. A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity. Proc. Natl. Acad. Sci. U.S.A. 2014, 111, E217–E226; (b) Cao, N.; Feng, S.-S. Doxorubicin conjugated to d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS): conjugation chemistry, characterization, in vitro and in vivo evaluation. Biomaterials 2008, 29, 3856–3865; (c) Wang, Y.; Li, L.; Jiang, W.; Yang, Z.; Zhang, Z. Synthesis and preliminary antitumor activity evaluation of a DHA and doxorubicin conjugate. Bioorg. Med. Chem. Lett. 2006, 16, 2974–2977; (d) Duhem, N.; Danhier, F.; Pourcelle, V.; Schumers, J. M.; Bertrand, O.; LeDuff, C. S.; Hoeppener, S.; Schubert, U. S.; Gohy, J. F.; Marchand-Brynaert, J.; Préat, V. Self-Assembling Doxorubicin–tocopherol succinate prodrug as a new drug delivery system: synthesis, characterization, and in vitro and in vivo anticancer activity. Bioconjug. Chem. 2014, 25, 72–81; (e) Kuznetsova, N. R.; Svirshchevskaya, E. V.; Skripnik, I. V.; Zarudnaya, E. N.; Benke, A. N.; Gaenko, G. P.; Molotkovskii, Y. G.; Vodovozova, E. L. Interaction of liposomes bearing a lipophilic doxorubicin prodrug with tumor cells. Biochem. (Mosc.) Suppl. Ser. A Membr. Cell Biol. 2013, 7, 12–20; (f) Stella, B.; Peira, E.; Dianzani, C.; Gallarate, M.; Battaglia, L.; Gigliotti, C. L.; Boggio, E.; Dianzani, U.; Dosio, F. Development and characterization of solid lipid nanoparticles loaded with a highly active doxorubicin derivative. Nanomaterials 2018, 8, 110.
[7] Li, W.; Fu, J.; Ding, Y.; Liu, D.; Jia, N.; Chen, D.; Hu, H. Low density lipoprotein-inspired nanostructured lipid nanoparticles containing pro-doxorubicin to enhance tumor-targeted therapeutic efficiency. Acta Biomater. 2019, 96, 456–467.
[8] Dos Santos Camara, A. L.; Nagel, G.; Tschiche, H. R.; Cardador, C. M.; Muehlmann, L. A.; de Oliveira, D. M.; Alvim, P. Q.; Azevedo, R. B.; Calderon, M.; Figueiro Longo, J. P. Acid-sensitive lipidated doxorubicin prodrug entrapped in nanoemulsion impairs lung tumor metastasis in a breast cancer model. Nanomedicine (Lond.) 2017, 12, 1751–1765.
[9] Bao, Y.; Yin, M.; Hu, X.; Zhuang, X.; Sun, Y.; Guo, Y.; Tan, S.; Zhang, Z. A safe, simple and efficient doxorubicin prodrug hybrid micelle for overcoming tumor multidrug resistance and targeting delivery. J. Control. Release 2016, 235, 182–194.
[10] Xiong, Q.; Cui, M.; Yu, G.; Wang, J.; Song, T. Facile Fabrication of reduction-responsive supramolecular nanoassemblies for co-delivery of doxorubicin and sorafenib toward hepatoma cells. Front. Pharmacol. 2018, 9, DOI: 10.3389/fphar.2018.00061.
[11] Tao, X.; Jia, N.; Cheng, N.; Ren, Y.; Cao, X.; Liu, M.; Wei, D.; Wang, F. Q. Design and evaluation of a phospholipase D based drug delivery strategy of novel phosphatidyl-prodrug. Biomaterials 2017, 131, 1–14.
[12] Yang, Z.; Gao, D.; Cao, Z.; Zhang, C.; Cheng, D.; Liu, J.; Shuai, X. Drug and gene co-delivery systems for cancer treatment. Biomater. Sci. 2015, 3, 1035–1049.
[13] Xiong, S.; Wang, Z.; Liu, J.; Deng, X.; Xiong, R.; Cao, X.; Xie, Z.; Lei, X.; Chen, Y.; Tang, G. A pH-sensitive prodrug strategy to co-deliver DOX and TOS in TPGS nanomicelles for tumor therapy. Colloids Surf. B 2019, 173, 346–355.
[14] Ni, S.; Qiu, L.; Zhang, G.; Zhou, H.; Han, Y. Lymph cancer chemotherapy: delivery of doxorubicin–gemcitabine prodrug and vincristine by nanostructured lipid carriers. Int. J. Nanomed. 2017, 12, 1565–1576.
[15] Kuai, R.; Yuan, W.; Son, S.; Nam, J.; Xu, Y.; Fan, Y.; Schwendeman, A.; Moon, J. J. Elimination of established tumors with nanodisc-based combination chemo- immunotherapy. Sci. Adv. 2018, 4, eaao1736.
[16] (a) Liu, J.; He, J.; Zhang, M.; Xu, G.; Ni, P. A synergistic polyphosphoester-based co-delivery system of the anticancer drug doxorubicin and the tumor suppressor gene p53 for lung cancer therapy. J. Mater. Chem. B 2018, 6, 3262–3273; (b) Pan, J.; Rostamizadeh, K.; Filipczak, N.; Torchilin, V. P. Polymeric co-Delivery systems in cancer treatment: An overview on component drugs' dosage ratio effect. Molecules 2019, 24, 1035; (c) Sun, H.; Yarovoy, I.; Capeling, M.; Cheng, C., Polymers in the co-delivery of siRNA and anticancer drugs for the treatment of drug-resistant cancers. Top Curr. Chem. (Cham.) 2017, 375, 24; (d) Kubo, S.; Takagi-Kimura, M.; Tagawa, M.; Kasahara, N. Dual-vector prodrug activator gene therapy using retroviral replicating vectors. Cancer Gene Ther. 2019, 26, 128–135.
[17] (a) Irby, D.; Du, C.; Li, F. Lipid-Drug conjugate for enhancing drug delivery. Mol. Pharm. 2017, 14, 1325–1338; (b) Sheng, R., Steroid-Based Supramolecular Systems and Their Biomedical Applications: Biomolecular Recognition and Transportation. In Chemistry and Biological Activity of Steroids, IntechOpen, London, UK, 2020, DOI: 10.5772/intechopen. 86752.